Her2V655 genotype and breast cancer progression in Korean women

被引:23
作者
An, HJ
Kim, NK
Oh, D
Kim, SH
Park, MJ
Jung, MY
Kang, H
Kim, SG
Lee, KP
Lee, KS
机构
[1] Pochon CHA Univ, Coll Med, Dept Pathol, Sungnam 463712, Kyonggi Do, South Korea
[2] Pochon CHA Univ, Coll Med, Inst Clin Res, Sungnam 463712, Kyonggi Do, South Korea
[3] Pochon CHA Univ, Coll Med, Dept Biostat, Sungnam 463712, Kyonggi Do, South Korea
[4] Pochon CHA Univ, Coll Med, Dept Surg, Sungnam 463712, Kyonggi Do, South Korea
关键词
breast cancer; codon; 655; Her2; polymorphism; Korean women;
D O I
10.1111/j.1440-1827.2005.01789.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The amplification and overexpression of Her2 proto-oncogene have been found to be associated with the development and progression of human breast cancer. A polymorphic valine allele at codon 655 of the Her2 gene (Her2(V655)) was suggested by some authors to be a susceptible genetic factor for the development of breast cancer. The Her2 polymorphism at codon 655 was investigated in 304 Korean women including 177 patients with breast cancer. The association between Her2 genotype and Her2 protein overexpression was also examined in breast cancers by immunohistochemistry. Her2(V655) was not associated with a significant breast cancer risk (odds ratio (OR), 1.792; 95% confidence interval (CI), 0.459-6.991). The frequency of homozygous or heterozygous valine allele increased in stage 2 patients (OR, 1.67; 95% CI, 0.67-4.19), and patients in stages 3 and 4 (OR, 3.36; 95% CI, 0.85-13.42) compared to patients in stage 0. However, an association between the presence of the valine allele and the overexpression of Her2 protein could not be demonstrated. These results suggest that Her2 polymorphism at codon 655 is not associated with the development of breast cancer in Korean women. However, there is a possibility that the valine allele at codon 655 might be related to increased risk of breast cancer progression.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 22 条
[1]   Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer [J].
Ameyaw, MM ;
Tayeb, M ;
Thornton, N ;
Folayan, G ;
Tariq, M ;
Mobarek, A ;
Evans, DAP ;
Ofori-Adjei, D ;
McLeod, HL .
JOURNAL OF HUMAN GENETICS, 2002, 47 (04) :172-175
[2]   MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
CELL, 1986, 45 (05) :649-657
[3]   ONCOGENIC ACTIVATION OF THE NEU-ENCODED RECEPTOR PROTEIN BY POINT MUTATION AND DELETION [J].
BARGMANN, CI ;
WEINBERG, RA .
EMBO JOURNAL, 1988, 7 (07) :2043-2052
[4]   Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [J].
Baxter, SW ;
Campbell, IG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (07) :557-558
[5]  
BERGER MS, 1988, CANCER RES, V48, P1238
[6]   A putative molecular-activation switch in the transmembrane domain of erbB2 [J].
Fleishman, SJ ;
Schlessinger, J ;
Ben-Tal, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (25) :15937-15940
[7]  
GREENE FL, 1997, AJCC CANC STAGING MA, P171
[8]   Distribution of HER2V655 genotypes in breast cancer cases and controls in the United States [J].
Keshava, C ;
McCanlies, EC ;
Keshava, N ;
Wolff, MS ;
Weston, A .
CANCER LETTERS, 2001, 173 (01) :37-41
[9]   A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer [J].
Kuraoka, K ;
Matsumura, S ;
Hamai, Y ;
Nakachi, K ;
Imai, K ;
Matsusaki, K ;
Oue, N ;
Ito, R ;
Nakayama, H ;
Yasui, W .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (04) :593-596
[10]  
LEMOINE NR, 1990, ONCOGENE, V5, P237